Cell & Gene Therapy Manufacturing 2026 - Size, Growth And Forecast Analysis

Cell & Gene Therapy Manufacturing 2026 - Size, Growth And Forecast Analysis

Growth in cell & gene therapy manufacturing services market is primarily driven by the high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments in advanced technologies by CDMOs, and increasing partnerships & agreements between pharmaceutical companies and CDMOs.  

 

However, the high operational costs associated with cell & gene therapy manufacturing are expected to restrain the growth of cell & gene therapy manufacturing services market to a certain extent. 

 

cell therapy accounted for the largest share of the cell & gene therapy manufacturing services market. This can primarily be attributed to factors such as increasing awareness about cell therapy, growing funding for new cell lines, increasing partnerships and acquisitions, and the development of advanced genomics methods for cell analysis. 

 

π†πžπ­ 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐒𝐠𝐑𝐭𝐬, π†π«πšπ› 𝐏𝐃𝐅 @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180609441 

 

The cell & gene therapy manufacturing services market is categorized into two segmentsβ€”clinical manufacturing and commercial manufacturing. The clinical manufacturing application segment accounted for the largest share of the cell & gene therapy manufacturing services market in 2020. The key factor driving this segment's growth are increasing awareness about cell therapy. 

 

Currently, there are 1,200 cell & gene therapies in trials worldwide. There are more than 700 investigational cell & gene therapies in clinical development in the US alone. However, manufacturing facilities have not kept up. It has been estimated that hundreds of facilities will be needed to manufacture the treatments that are now in clinical trials. 

 

According to a 2020 PhRMA report on the cell & gene therapy pipeline in 2018, there were 289 cell & gene therapies in clinical development by biopharmaceutical companies. This number increased by 25% in 2020, with 362 cell & gene therapies in clinical development. 

 

The high growth rate in this segment can be attributed to the increasing expenditure on R&D by pharmaceutical & biotechnology companies, rising collaborations between pharmaceutical and biotechnology companies, and the growing number of cell & gene therapies in the R&D pipeline.